Han Juanjuan, Dinculescu Astra, Dai Xufeng, Du Wei, Smith W Clay, Pang Jijing
Eye Hospital, School of Ophthalmology & Optometry, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Department of Ophthalmology, University of Florida, Gainesville, FL.
Mol Vis. 2013 Dec 20;19:2579-89.
Mouse models are useful tools for developing potential therapies for human inherited retinal diseases, such as retinitis pigmentosa (RP), since more strains are being identified with the same mutant genes and phenotypes as humans with corresponding retinal degenerative diseases. Mutations in the beta subunit of the human rod phosphodiesterase (PDE6B) gene are a common cause of autosomal recessive RP (arRP). This article focuses on two well-established naturally occurring mouse models of arRP caused by spontaneous mutations in Pde6b, their discovery, phenotype, mechanism of degeneration, strengths and limitations, and therapeutic approaches to restore vision and delay disease progression. Viral vector, especially adeno-associated viral vector (AAV) -mediated gene replacement therapy, pharmacological treatment, cell-based therapy and other approaches that extend the therapeutic window of treatment, is a potentially promising strategy for improving photoreceptor function and significantly slowing the process of retinal degeneration.
小鼠模型是开发人类遗传性视网膜疾病(如色素性视网膜炎,RP)潜在疗法的有用工具,因为越来越多的品系被鉴定出具有与患有相应视网膜退行性疾病的人类相同的突变基因和表型。人类视杆磷酸二酯酶(PDE6B)基因β亚基的突变是常染色体隐性RP(arRP)的常见病因。本文重点关注两种由Pde6b自发突变引起的成熟的arRP自然发生小鼠模型、它们的发现、表型、退化机制、优势和局限性,以及恢复视力和延缓疾病进展的治疗方法。病毒载体,尤其是腺相关病毒载体(AAV)介导的基因替代疗法、药物治疗、基于细胞的治疗以及其他扩展治疗窗口期的方法,是改善光感受器功能并显著减缓视网膜退化进程的潜在有前景的策略。